• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Merck looks ahead to a COVID-19 drug and vaccine—and a Gardasil recovery—as pandemic takes...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 27, 2020 at 11:23: PM
via The pharma giant said Tuesday that COVID-19 would take a $2.5 billion bite out of its 2020 revenue, more than the $1.9 billion it had previously predicted. Growth in drugs that didn’t take a pandemic hit has softened that blow. In a quote-unquote normal year, though, Merck might be reporting sales growth of 8% to 10%, not the 1% it posted for Q3.

article source
 




Top Bottom
Back
Quote